EUVIMEDEUVIMED entdecken
Open Access

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

Robert A Fletcher iD, Clare Arnott iD, Patrick Rockenschaub iD, Aletta E Schutte iD, Lewis Carpenter iD, Muthiah Vaduganathan iD, Rajiv Agarwal iD, George Bakris iD, Tara I Chang iD, Hiddo J L Heerspink iD, Meg J Jardine iD, Kenneth W Mahaffey iD und 6 weitere

Journal of the American Heart Association · 2023

DOI: 10.1161/jaha.122.028516 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Robert A Fletcher und 17 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health, UNSW New South Wales Sydney Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic, Heart Failure. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium glucose cotransporter‐2 inhibitors reduce systolic blood pressure (SBP), but whether they affect SBP variability is unknown. There also remains uncertainty regarding the prognostic value of SBP variability for different clinical outcomes. Methods and Results Using individual participant data from the CANVAS (Canagliflozin Cardiovascular Assessment Study) Program and CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial, we assessed the effect of canagliflozin on SBP variability in people with type 2 diabetes across 4 study visits over 1.5 years as measured by standard deviation, coefficient of variation, and variability independent of the mean. We used multivariable Cox regression models to estimate associations of SBP variability with cardiovascular, kidney, and mortality outcomes. In 11 551 trial participants, canagliflozin modestly lowered the standard deviation of SBP variability (−0.25 mm Hg [95% CI, –0.44 to −0.06]), but there was no effect on coefficient of variation (0.02% [95% CI, –0.12 to 0.16]) or variability independent of the mean (0.08 U [95% CI, –0.11 to 0.26]) when adjusting for correlation with mean SBP. Each 1 standard deviation increase in standard deviation of SBP variability was independently associated with higher risk of hospitalization for heart failure (hazard ratio [HR], 1.19 [95% CI, 1.02–1.38]) and all‐cause mortality (HR, 1.12 [95% CI, 1.01–1.25]), with consistent results observed for coefficient of variation and variability independent of the mean. Increases in SBP variability were not associated with kidney outcomes.

Conclusions

In people with type 2 diabetes at high cardiovascular risk or with chronic kidney disease, higher visit‐to‐visit SBP variability is independently associated with risks of hospitalization for heart failure and all‐cause mortality. Canagliflozin has little to no effect on SBP variability, independent of its established SBP‐lowering effect. Registration URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT01032629, NCT01989754, NCT02065791.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsRenal Insufficiency, ChronicHeart FailureCardiovascular DiseasesHumansCanagliflozinBlood PressureKidney

Stichwörter der Autor:innen

SGLT2 inhibitorsblood pressure variabilitycanagliflozinclinical outcomesclinical trials

Substanzen

CanagliflozinSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • The George Institute for Global Health, UNSW New South Wales Sydney Australia.
  • Department of Cardiology Royal Prince Alfred Hospital New South Wales Sydney Australia.
  • Sydney Medical School University of Sydney New South Wales Australia.
  • Charité Lab for Artificial Intelligence in Medicine Charité Universitätsmedizin Berlin Berlin Germany.
  • QUEST Center for Transforming Biomedical Research Berlin Institute of Health (BIH) Berlin Germany.
  • Faculty of Medicine and Health UNSW New South Wales Sydney Australia.

ORCID-Profile: Robert A Fletcher, Clare Arnott, Patrick Rockenschaub, Aletta E Schutte, Lewis Carpenter, Muthiah Vaduganathan, Rajiv Agarwal, George Bakris, Tara I Chang, Hiddo J L Heerspink, Meg J Jardine, Kenneth W Mahaffey, Bruce Neal, Carol Pollock, Anthony Rodgers, Vlado Perkovic, Brendon L Neuen

Zitieren

APA

Fletcher, R. A., Arnott, C., Rockenschaub, P., Schutte, A. E., Carpenter, L., Vaduganathan, M., Agarwal, R., Bakris, G., Chang, T. I., Heerspink, H. J. L., Jardine, M. J., Mahaffey, K. W., Neal, B., Pollock, C., Jun, M., Rodgers, A., Perkovic, V., & Neuen, B. L. (2023). Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.028516

Vancouver

Fletcher RA, Arnott C, Rockenschaub P, Schutte AE, Carpenter L, Vaduganathan M, et al. Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.028516

BibTeX
@article{Fletcher2023,
  author = {Fletcher, Robert A and Arnott, Clare and Rockenschaub, Patrick and Schutte, Aletta E and Carpenter, Lewis and Vaduganathan, Muthiah and Agarwal, Rajiv and Bakris, George and Chang, Tara I and Heerspink, Hiddo J L and Jardine, Meg J and Mahaffey, Kenneth W and Neal, Bruce and Pollock, Carol and Jun, Min and Rodgers, Anthony and Perkovic, Vlado and Neuen, Brendon L},
  title = {Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials},
  journal = {Journal of the American Heart Association},
  year = {2023},
  doi = {10.1161/jaha.122.028516}
}
Kostenlos starten →